Product news from the 02/06/07 news brief

Share this article:
GlaxoSmithKline said that the FDA has issued an approvable letter for its anti-clotting drug Arixtra (fondaparinux sodium). Glaxo is seeking approval to market the drug for use in treating unstable angina, or myocardial infarction. Arixtra is already approved for use during surgery in patients at risk for blood clots. Glaxo said in a statement that it would continue working with the FDA to provide the additional information requested to complete the assessment of Arixtra Global Arixtra sales totaled $44 million in 2005. Novo Nordisk received FDA approval for NovoLog (insulin aspart [rDNA origin] injection) for a pregnancy Category B rating, further validating the drug as a safe and effective treatment for pregnant women with Type 1 diabetes and their unborn children.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.